Comparing different dosing schedules of Vismodegib for advanced skin cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the tolerability and effectiveness of four different dosing schedules of Vismodegib, a medication used for advanced basal cell carcinoma. Participants will be assigned to either personalized intermittent dosing schedules or fixed intermittent and continuous dosing regimens. The study will involve adult patients with confirmed locally advanced basal cell carcinoma, and it will assess how well these different approaches manage the condition. The goal is to identify the most effective and patient-friendly dosing strategy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a cytologically or histologically confirmed locally advanced basal cell carcinoma. (Nodal involvement permitted)
* Adult males or females 18 years of age or older at time of signing informed consent. All races and ethnicities are eligible, and no upper limit of age is specified.
* Must have ability to comprehend and the willingness to sign written informed consent for study participation.
* Patients must have at least one cutaneous tumor site amenable to direct and accurate measurement by ruler/calipers.
* Patients may have received prior hedgehog inhibitor therapy (if more than 6 months prior) or other systemic treatments for basal cell carcinoma in the past.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2
* Agreement not to donate blood or blood products during the study and for 24 months after discontinuation of vismodegib.
* Patients must have adequate hepatic, renal, and bone marrow function as defined in the protocol.
* Participants must have a negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year.
* Women of reproductive potential are required to use two forms of acceptable contraception (including one acceptable barrier method with spermicide) during therapy and for 24 months after completing therapy.
* Female patients must agree not to become pregnant or donate lactation during treatment and until 24 months after stop of treatment. Male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 3 months after the last dose to avoid exposing a pregnant partner and unborn fetus to vismodegib. Male patients must agree not to donate sperm during the study and for 3 months after discontinuation of vismodegib.

Exclusion Criteria:

* Received prior hedgehog inhibitor therapy in the last 6 months
* Female patients who are pregnant, intend to become pregnant or are nursing.
* Uncontrolled intercurrent illness including, but not limited to, serious infection. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
* Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment.
* Inability or unwillingness to swallow capsules.
* Any known allergy, hypersensitivity or severe reaction to vismodegib or any of the ingredients
* Co-treatment with a statin or St. John's Wort.

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting

Study contacts

• Principal investigator: Zeynep Eroglu, MD — Moffitt Cancer Center
• Study coordinator: Sy Olson-Mcpeek
• Email: sy.olson-mcpeek@moffitt.org
• Phone: 813-745-0935

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• At-home cancer treatment versus clinic-based treatment for advanced cancer patients

  This study tests whether giving cancer treatment at home is better for comfort and satisfaction compared to getting it at a clinic for people with advanced cancer.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Jacksonville, Florida and 1 other locations · NCT05969860

• Melanoma treatment with immunotherapy guided by serial ctDNA testing

  This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07930182

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• See if SAVI Scout MD helps surgeons localize breast cancer more precisely

  This study tests whether the SAVI Scout MD radar reflectors help surgeons find and remove breast cancer more accurately, potentially reducing the need for a second operation.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07686250

• PIPAC with Mitomycin C for unresectable peritoneal cancer

  This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07487168

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.